[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-lymphocytic-chronic-b-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-lymphocytic-chronic-b-cell":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,56,79,98,118,144,167,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100544095","phase-1-anti-cd19-chimeric-antigen-receptor-t-cell-immunotherapy-for-leukemias-100544095",false,"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","Phase I\u002FII Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for B-cell Leukemias","* INCLUSION CRITERIA:\n* Malignancy criteria\n\n  * Histologically confirmed participants with either CLL or SLL or B-cell acute lymphoblastic leukemia or lymphoma (ALL) via immunohistochemical or flow cytometry methods will be eligible. Participants with evidence of Richter s transformation of CLL\u002FSLL are also eligible. Participants with Richter s transformation must have current or prior evidence of CLL, confirmed by review of a current or prior histological sample by NIH pathologists or confirmed by flow cytometry performed at the NIH.\n  * Demonstration of CD19 expression on CLL\u002FSLL or ALL, as assessed by the NCI Laboratory of Pathology or NIH Department of Laboratory Medicine Hematopathology section. For participants with pathologically confirmed Richter s transformation, the transformed cells must also have CD19 expression.\n  * CD19 expression must be uniform meaning no populations of clearly CD19-negative CLL\u002FSLL, Richter s or ALL cells are observed.\n  * CD20 must be detected on \\>= 20% of malignant cells by flow cytometry or immunohistochemistry. Documentation of CD20 expression is not required for patients who have received CD20-directed therapy within 90 days prior to the date of enrollment.\n  * The last dosage of systemic therapy (including corticosteroids) must be at least 14 days prior to the first dose of rituximab, with the exceptions of BTK inhibitors (BTKi) for CLL\u002FSLL and tyrosine kinase inhibitors (TKI) for ALL. Participants who were receiving a BTKi for CLL\u002FSLL or a TKI for ALL for at least 14 days prior to protocol enrollment can continue these agents during part of the time the participants are enrolled on this clinical trial.\n  * For participants who have received antibodies targeting CD19, at least sixty days must elapse between therapy with antibodies targeting CD19 and CAR T-cell infusion.\n  * Participants with CLL\u002FSLL must have received at least two prior treatment regimens, at least one of which must have contained a Bruton s tyrosine kinase (BTK) inhibitor. Participants who took a BTK inhibitor but stopped due to intolerance are potentially eligible. Participants with relapsed or refractory CLL\u002FSLL after alloHSCT are eligible.\n  * Participants with refractory ALL that failed induction or participants with relapsed ALL after a standard induction regimen or after any later line of therapy are eligibleParticipants with relapsed or refractory ALL after alloHSCT are eligible.\n  * All participants must have measurable malignancy as defined by at least one of the criteria below.\n\n    * Presence of CLL,SLL, or ALL masses that are measurable (minimum 1.5 cm in largest diameter) by CT scan or PET\u002FCT is required unless bone marrow or blood involvement with malignancy is detected.\n    * For CLL\u002FSLL or ALL with only bone marrow and\u002For blood involvement, no mass is necessary, but if a mass is not present, bone marrow and\u002For blood malignancy must be detectable by flow cytometry. Any level of CLL\u002FSLL or ALL detectable by flow cytometry is sufficient.\n* Other inclusion criteria:\n\n  * Age \\>= 18 years.\n  * Performance status (ECOG) 0-1.\n  * Participants must have adequate organ and marrow function as defined below:\n\n    * ANC \\>= 1,000\u002FmcL without the support of filgrastim or other growth factors in the 10 days prior to screening assessment\n    * platelets \\>= 50,000\u002FmcL without transfusion support\n    * hemoglobin \\>= 8 g\u002FdL\n    * total bilirubin \\\u003C= 2.0 mg\u002FdL\n    * ALT or AST Serum ALT and AST less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated. If liver involvement with malignancy is detected, ALT and AST must be less than or equal to 5 times the upper limit of normal\n    * Serum Creatinine Serum creatinine levels \\\u003C 1.5 X institutional ULN. Participants with serum creatinine \\>= 1.5 X institutional ULN may participate if serum creatinine eGFR is \\>=50 mL\u002Fmin\u002F1.73m\\^2 by 2021 CKD-EPI equation.\n\n      * ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase);\n      * AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.\n      * (A)Creatinine clearance (CrCl) or eGFR should be calculated per institutional standard.\n  * For CLL participants, B cells must make up less than 95% of blood lymphocytes on a lymphocyte phenotyping profile TBNK at the time of screening assessment. For ALL participants, the peripheral blood blast percentage on CBC differential must be 1% or less.\n  * Room air oxygen saturation of 92% or greater\n  * Participants of child-bearing or child-fathering potential must be willing to practice abstinence or highly effective contraception starting at the time of study entry, for the duration of study therapy, and for 12 months after receiving the protocol treatment.\n  * Participants must agree not to donate eggs for 12 months after receiving the protocol treatment\n  * Participants who are breastfeeding must be willing to cease breastfeeding from study treatment initiation through 12 months after the last dose of the study drugs.\n  * Participants must have a negative blood PCR test for hepatitis B DNA. If hepatitis B DNA (PCR) testing is not available, participants must have a negative hepatitis B surface antigen and negative hepatitis B core antibody test.\n  * Participants must have a negative blood PCR test for hepatitis C RNA. Only if Hepatitis C PCR testing is not available in a timely manner, participants must have a negative Hepatitis C antibody test.\n  * Cardiac ejection fraction of greater than or equal to 50% by echocardiography and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 30 days prior to treatment start.\n  * All participants must have the ability to understand and willingness to sign a written informed consent.\n  * All participants must be willing to undergo mandatory biopsies during the study.\n\nEXCLUSION CRITERIA:\n\n* Participants who are receiving any other investigational agents.\n* Participants who have had prior CAR T-cell therapy.\n* Participants who have had a live-attenuated or viral vector-based vaccine in the last 60 days prior to pre-leukapheresis rituximab. Participants who plan to receive a live attenuated or viral vector-based vaccine within the first 100 days after CAR T-cell infusion.\n* Participants that require urgent therapy due to tumor mass effects or spinal cord compression.\n* Current\u002Factive HIV infection, as measured by seropositivity for HIV antibody.\n* Participants with second malignancies in addition to their CLL or ALL are not eligible if the second malignancy has required treatment with surgery, radiation or chemotherapy, or other therapies within the past 2 years or is not in complete remission. Exceptions are that, in the last 2 years, participants may have had successful resection of non-metastatic basal cell or squamous cell carcinoma of the skin, and participants may have received hormonal therapy for fully resected breast cancer.\n* Positive beta Human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test in women of childbearing potential (WOCBP) performed at screening.\n* Active uncontrolled systemic infections (defined as infections causing fevers within 48 hours of the date of planned protocol rituximab or chemotherapy start and infections requiring intravenous antibiotics when intravenous antibiotics have been administered for less than 72 hours at the time of protocol rituximab or chemotherapy start). There must be objective evidence of infection, including, but not limited to, a positive blood, urine or sputum culture, positive nasal swab or blood test for viral infection, or the appearance of infiltrates on imaging of the lung.\n* Active coagulation disorders, major uncontrolled medical illnesses of the cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary or immune system, history of myocardial infarction, history of ventricular tachycardia or ventricular fibrillation, active cardiac arrhythmias with the exception of atrial fibrillation with baseline heart rates less than or equal to 90 beats per minute, (Use of medications to control heart rate is allowed.), active obstructive or restrictive pulmonary disease, or active autoimmune diseases such as rheumatoid arthritis. These include uncontrolled intercurrent illness manifesting as electrolyte derangements or as assessed by chemistries.\n* Significant neurologic disorders, including a history of a seizure disorder as an adult, that are not completely and permanently resolved and not requiring current treatment.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease) that has not been cured by a prior allogeneic stem cell transplant.\n* For participants that have not had prior allogeneic stem cell transplant: Systemic corticosteroid steroid therapy of any dose greater than 5 mg\u002Fday or more of prednisone or equivalent is not allowed within 14 days prior to the first dose of rituximab. Corticosteroid creams, ointments, and eye drops are allowed.\n* For participants that have had prior allogeneic stem cell transplant: Receiving any systemic immunosuppressive drugs including corticosteroids at doses of greater than 5 mg\u002Fday prednisone or equivalent within 28 days prior to Rituximab. Topical corticosteroid preparations applied to the skin such as solutions, creams, and ointments are allowed. Inhaled corticosteroids are allowed, and corticosteroid eye drops are allowed.\n* History of severe immediate hypersensitivity reaction to any of the agents used in this study, including hypersensitivity to aminoglycoside antibiotics, which may be used in the cell culture media.\n* Participants with CNS3 disease, neurologic signs of CNS disease, radiologically detected active CNS lymphoma or meningeal involvement.\n* Checkpoint inhibitor drugs such as pembrolizumab or nivolumab or other antibodies targeting PD-1 or PDL-1 within 180 days of pre-leukapheresis rituximab. This is because of possible effects checkpoint inhibitor therapy could have on the participant's T cells.\n* Known active alcohol or drug abuse.\n* History of allergy to study drug components.\n* Active tumor lysis syndrome as assessed by serum uric acid, LDH, calcium, and phosphorus.\n* Active rhabdomyolysis as assessed by elevated CK and acute change in renal function as reflected by increased creatinine and blood urea nitrogen (BUN).\n* Active diabetic ketoacidosis or hyperosmolar hyperglycemic state, as assessed by serum glucose. The urine will be tested for ketones if serum glucose is over 350 mg\u002FdL at screening.\n* Participants who received a previous allogeneic HSCT must have no (grade 0) acute GVHD (Appendix H) and either no chronic GVHD or mild chronic GVHD. Participants with GVHD meeting the above criteria with local therapy (topical cutaneous steroids, inhaled steroids, and eye drops) will be eligible for enrollment.","ALL","18 Years","120 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Background:\n\nChronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers can modify a person's own immune cells (T cells) to target CD19. When these modified T cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer cells.\n\nObjective:\n\nTo test anti-CD19 CAR T cell therapy in people with CLL or SLL and ALL.\n\nEligibility:\n\nPeople aged 18 years and older with CLL or SLL and ALL that has not been controlled with standard drugs.\n\nDesign:\n\nParticipants will be screened. They will have imaging scans and tests of their heart function. If a sample of tissue from their tumor is not available, a new one may be taken; the sample will be tested for CD19.\n\nParticipants will receive a drug to reduce the leukemia cells in their blood. Then they will undergo apheresis: Blood will be taken from the body through a needle. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different needle. The collected T cells will be gene edited to make them attack cells with CD19.\n\nParticipants will take drugs to prepare them for treatment for 3 days. These drugs will start 5 days before the treatment. Then their own modified CAR T cells will be returned to their bloodstream. Participants will stay in the hospital for at least 9 days after the treatment.\n\nFollow-up visits will continue for 5 years.",[28,29,30,31,32,33,34],"Leukemia, Lymphocytic, Chronic, B-Cell","B-Lymphocytic Leukemia, Chronic","B-Cell Chronic Lymphocytic Leukemia","Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Leukemia, Acute Lymphoblastic","Small Lymphocytic Lymphoma",[34,36,37,38,39,40,41,42,16,31],"Immunotherapy","CLL","Chronic Lymphocytic Leukemia","Chimeric Antigen Receptors","Autologous T Cells Infusion","Adoptive T Cell Therapy","CAR","RECRUITING","2026-06-23",{"date":46,"type":47},"2026-06-24","ACTUAL",{"date":49,"type":47},"2024-09-03",{"date":51,"type":21},"2030-07-01",{"name":53,"class":54},"National Cancer Institute (NCI)","NIH",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":55},"100640477","a-real-world-study-of-ibrutinib-and-venetoclax-iv-first-line-treatment-given-for-fixed-duration-of-time-in-participants-with-chronic-lymphocytic-leukemia-100640477","NCT07602088","A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia","Prospective Cohort Study With Fixed-Duration Ibrutinib + Venetoclax (I+V) First-Line Treatment in Patients With Chronic Lymphocytic Leukemia in a Real-World Setting","REALITY-RO","Inclusion Criteria\n\n* Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) requiring treatment according to international workshop on chronic lymphocytic leukemia (iwCLL) 2018 guidelines\n* Intented for the treatment with fixed-duration ibrutinib plus venetoclax treatment (I+V) according to the approved indication. Decision to start I+V treatment must have been taken before and independently of participant's inclusion in the study\n* Participant must sign an informed consent form (ICF) allowing source data verification in accordance with local requirements\n* Is able to read, understand, and complete the PRO instruments in local language and comply with completion of all patient-reported outcome (PRO) instruments\n\nExclusion Criteria\n\n* Has a history of CLL\u002FSLL treatment\n* Has received an investigational medicinal product (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study or the first data collection time point\n* Is currently enrolled or plans to participate in an interventional clinical study (participation in a non-Janssen sponsored non-interventional study or registry is allowed)\n* Falls under any restrictions or limitations preventing treatment with I+V as per the current approved label of ibrutinib or venetoclax in Romania",{"count":65,"type":21},60,"OBSERVATIONAL","The purpose of this study is to see how well Ibrutinib and Venetoclax (I+V) treatment works (effectiveness) for participants with chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL) when it is used in routine, everyday medical care.",[28],"2026-06-04",{"date":71,"type":47},"2026-06-05",{"date":73,"type":47},"2026-05-18",{"date":75,"type":21},"2029-11-30",{"name":77,"class":78},"Janssen Research & Development, LLC","INDUSTRY",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":55},"100539107","benefits-of-individual-physical-activity-intervention-on-health-related-quality-of-life-in-participants-with-chronic-lymphocytic-leukemia-100539107","NCT06299540","Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia","Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice","QOLIBRI","Inclusion Criteria:\n\n* Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)\n* Participants agreed to follow the individual physical activity intervention (IPAI)\n* Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet\n* Participants with Internet access at home and email address\n* Participants agreed to wear a connected watch 24 hours a day for all the duration of the study\n\nExclusion Criteria:\n\n* Pregnant participants or planning to become pregnant while enrolled in this study\n* Participants with inability or deemed unsafe to practice physical activity\n* Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit\n* Participants who are currently involved in an interventional study\n* Participants with probable difficulties in using the digital tool autonomously",{"count":88,"type":21},180,"The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).",[28],{"date":71,"type":47},{"date":93,"type":47},"2024-05-27",{"date":95,"type":21},"2027-10-29",{"name":97,"class":78},"Janssen Cilag S.A.S.",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100513254","phase-2-a-study-to-customize-ibrutinib-treatment-regimens-for-participants-with-previously-untreated-chronic-lymphocytic-leukemia-100513254","NCT05963074","A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia","TAILOR","Inclusion Criteria:\n\n* Diagnosis of chronic lymphocytic leukemia\u002F small lymphocytic lymphoma (CLL\u002FSLL) as per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 diagnostic criteria\n* For ibruinib + venetocIax (I+V) cohorts: eastern cooperative oncology group (ECOG) performance status of 0-1. For ibrutinib monotherapy cohorts: ECOG performance status of 0-2\n* Measurable nodal disease by computed tomography (CT), defined as at least 1 lymph node greater than and equal to (\\>=) 1.5 centimeters (cm) in longest diameter\n* A participant using oral contraceptives must use an additional contraceptive method\n* A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or until 1 month after last dose or per local label if more conservative (for example, 3 months in European Union or Canada and 1 month in United States)\n\nExclusion Criteria:\n\n* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura, such as those participants with a declining hemoglobin level or platelet count secondary to autoimmune destruction within the 4 weeks prior to first dose of study treatment, or the need for prednisone greater than (\\>) 20 milligrams (mg) daily (or corticosteroid equivalent) to treat or control the autoimmune disease\n* Known bleeding disorders (example, von Willebrand's disease or hemophilia)\n* Stroke or intracranial hemorrhage within 6 months prior to enrollment\n* Known or suspected Richter's transformation or central nervous system (CNS) involvement\n* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class II, III, or IV congestive heart failure as defined by the New York Heart Association Functional Classification",{"count":107,"type":21},320,[25],"The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).",[28,34],{"date":71,"type":47},{"date":113,"type":47},"2024-05-30",{"date":115,"type":21},"2029-03-19",{"name":77,"class":78},74,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100512084","phase-3-a-study-of-nemtabrutinib-plus-venetoclax-vs-venetoclax--rituximab-vr-in-second-line-2l--relapsedrefractory-rr-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll-mk-1026-010bellwave-010-100512084","NCT05947851","A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) (MK-1026-010\u002FBELLWAVE-010).","A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)","Inclusion Criteria:\n\n* Confirmed diagnosis of chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL) and active disease clearly documented to initiate therapy\n* Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, and immunoglobulin heavy chain gene (IGHV) mutation status results required before randomization for Part 2 participants only\n* Relapsed or refractory to at least 1 prior available therapy\n* Have at least 1 marker of disease burden\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization\n* Has a life expectancy of at least 3 months\n* Has the ability to swallow and retain oral medication\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening\n* Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria\n* Participants with adequate organ function with specimens collected within 7 days before the start of study intervention\n* If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception\n* Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding\n\nExclusion Criteria:\n\n* Has an active hepatitis B virus\u002F hepatitis C virus (HBV\u002FHCV) infection\n* Has gastrointestinal (GI) dysfunction that may affect drug absorption\n* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL\u002FSLL\n* Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease and\u002For acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening\n* Clinically significant cardiovascular disease\n* Has a known allergy\u002Fsensitivity to nemtabrutinib or contraindication to venetoclax\u002Frituximab (or rituximab biosimilar), or any of the excipients\n* Has history of severe bleeding disorders (eg, hemophilia)\n* Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization\n* Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within ≤ 12 months before randomization or has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids\n* Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.\n* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention\n* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration\n* Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications",{"count":126,"type":21},735,[128],"PHASE3","The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R\u002FR CLL\u002FSLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).",[28,131,132,133,37,134],"Leukemia, Chronic Lymphocytic","Small-Cell Lymphoma","Lymphoma, Small Lymphocytic","SLL","2026-05-14",{"date":73,"type":47},{"date":138,"type":47},"2023-08-08",{"date":140,"type":21},"2035-07-01",{"name":142,"class":78},"Merck Sharp & Dohme LLC",54,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100311193","phase-1-study-evaluating-safety-and-efficacy-of-jcar017-in-subjects-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll-100311193","NCT03331198","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","An Open-Label, Phase 1\u002F2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)","Inclusion Criteria:\n\n* Diagnosis of:\n\n  1. CLL with an indication for treatment based on the Investigator's opinion and measurable disease, or\n  2. SLL (lymphadenopathy and\u002For splenomegaly and \\\u003C 5×10\\^9 CD19+ CD5+ clonal B lymphocytes\u002FL \\[\\\u003C 5000\u002FµL\\] in the peripheral blood at diagnosis with measurable disease that is biopsy-proven SLL)\n* Subjects (other than those in the ibrutinib + JCAR017 combination therapy and DEME cohort) must have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy.\n* Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows:\n\n  1. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and high-risk features must have failed at least 2 lines of prior therapy.\n  2. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and standard-risk features must have failed at least 3 lines of prior therapy.\n  3. DEME cohort ONLY: Subjects with relapsed or refractory CLL or SLL, irrespective of cytogenetic risk features, must have received at least 2 lines of prior therapy including a BTKi and a BCL2i.\n* Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:\n\n  1. be receiving ibrutinib and progressing at the time of study enrollment\n  2. be receiving ibrutinib for at least 6 months with a response less than complete response\u002Fremission (CR) and have high-risk features as defined in inclusion criterion 5a\n  3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without progression on ibrutinib\n  4. have previously received ibrutinib and have no contraindications to restarting ibrutinib\n* Eastern Cooperative Oncology Group performance status of ≤ 1\n* Assessed by the Investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy\n* Adequate organ function, defined as:\n\n  1. Serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) OR calculated creatinine clearance \\> 30 mL\u002Fmin\n  2. Alanine aminotransferase ≤ 5 × ULN and total bilirubin \\\u003C 2.0 mg\u002FdL (or \\\u003C 3.0 mg\u002FdL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)\n  3. Adequate pulmonary function, defined as ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air\n  4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility\n* Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.\n* If prior CD19-targeted therapy has been administered, subject must have CD19-positive disease confirmed by immunohistochemistry or flow cytometry since completing the prior CD19-targeted therapy.\n* Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and have received prior therapy with venetoclax\n* Subjects in venetoclax + JCAR017 combination cohort must:\n\n  1. have failed at least 1 prior line of therapy, including failed BTKi therapy or have been deemed ineligible to receive BTKi\n  2. be venetoclax naive (required for dose expansion) or\n  3. if prior venetoclax (only for dose escalation)\n  4. have no contraindictions to re-initiation of venetoclax based on prior intolerance and have had at least 6 months elapsed since the last dose of venetoclax, if either, best response was stable disease, or subject experienced disease progression on venetoclax, or within 6 months of venetoclax discontinuation\n* subjects in the venetoclax + JCAR017 combination must have hemoglobin \\>=9 g\u002FdL, absolute neutrophil count \\>=500mm3 and platelets\\>= 75,000\u002Fmm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow\n* must have diagnosis of CLL or SLL with an indication for treatment based on the investigator's opinion and measurable disease (any of the following measurable lymph nodes ≥1.5 cm in the greatest transverse diameter and\u002For hepatomegaly or splenomegaly) and demonstration of CLL cells in the peripheral blood by flow cytometry\n\nExclusion Criteria:\n\n* Subjects with known active central nervous system (CNS) involvement by malignancy. Those with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging.\n* History of another primary malignancy that has not been in remission for at least 2 years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer, completely resected stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.)\n* Subjects with Richter's transformation\n* Prior treatment with any gene therapy product\n* Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV) infection\n* Systemic fungal, bacterial, viral, or other infection that is not controlled\n* Presence of acute or extensive chronic graft versus host disease (GVHD)\n* History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease\n* History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or psychosis\n* Pregnant or nursing (lactating) women\n* Use of any of the following medications or treatments within the noted time prior to leukapheresis:\n\n  1. Alemtuzumab within 6 months prior to leukapheresis\n  2. Allogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresis\n  3. Cladribine within 3 months prior to leukapheresis\n  4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis\n  5. Radiation including large bone marrow fields such as sternum or pelvis within 6 weeks prior to leukapheresis\n  6. Fludarabine within 4 weeks prior to leukapheresis\n  7. GVHD therapies such as calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive antibodies (such as anti-tumor necrosis factor-α \\[TNFα\\], anti-interleukin-6 \\[IL-6\\], or anti-interleukin-6 receptor \\[IL 6R\\]) within 4 weeks prior to leukapheresis\n  8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2 weeks prior to leukapheresis\n  9. Therapeutic doses of corticosteroids (defined as \\> 20 mg\u002Fday prednisone or equivalent) within 7 days prior to leukapheresis\n  10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis\n  11. Venetoclax within 4 days prior to leukapheresis\n  12. Idelalisib or duvelisib within 2 days prior to leukapheresis\n  13. Lenalidomide or covalent and non-covalent BTKi within 1 day prior to leukapheresis\n  14. Experimental agents, including off-label use of approved drugs (with the exception of acalabrutinib which may be continued up to the day before leukapheresis), within 4 weeks prior to leukapheresis unless progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis\n* Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocol\n* Progressive vascular tumor invasion, thrombosis, or embolism\n* Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation\n* Use of any of the following medications or treatments within the noted time prior to leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis experimental agents, including off-label use of approved drugs, within 4 weeks prior to leukapheresis.\n* Venous thrombosis or embolism requiring treatment but not managed on a stable regimen of anticoagulation\n* For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant treatment with CYP3A moderate\u002Fstrong inducers or moderate\u002Fstrong inhibitors which cannot be discontinued",{"count":107,"type":21},[24,25],"This is a Phase 1\u002F2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.",[28,133],[156],"TRANSCEND_CLL_004","2026-03-02",{"date":159,"type":47},"2026-03-04",{"date":161,"type":47},"2017-11-27",{"date":163,"type":21},"2027-11-26",{"name":165,"class":78},"Juno Therapeutics, a Subsidiary of Celgene",86,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":55},"100104689","family-study-of-lymphoproliferative-disorders-100104689","NCT00626496","Family Study of Lymphoproliferative Disorders","Genetic Epidemiology of Lymphoproliferative Disorders","At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.",true,"100 Years",{"count":177,"type":21},3000,"Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.",[180,28,181,182,183],"Lymphoma, Non-Hodgkin","Lymphoma, B-Cell","Monoclonal B-Cell Lymphocytosis","Multiple Myeloma","2025-10-09",{"date":186,"type":47},"2025-10-14",{"date":188,"type":47},"2004-04-01",{"date":190,"type":21},"2029-12-31",{"name":192,"class":193},"Mayo Clinic","OTHER",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":203,"studyType":66,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":55},"100275765","institut-paoli-calmettes-chronic-lymphatic-leukemia-database-100275765","NCT02869529","Institut Paoli Calmettes Chronic Lymphatic Leukemia Database","Inclusion Criteria:\n\n* Diagnosis of chronic lymphatic leukemia\n\nExclusion Criteria:\n\n* Score of Matutes \\\u003C4","95 Years",{"count":202,"type":21},4200,"10 Years","Database of Institut Paoli-Calmettes patients diagnosed with chronic lymphatic leukemia",[28],"2016-08-16",{"date":208,"type":21},"2016-08-17",{"date":210,"type":4},"2006-01",{"date":212,"type":21},"2030-12",{"name":214,"class":193},"Institut Paoli-Calmettes"]